Supplemental Appendix

Covariates Included in Disease Risk Index

Medication use in 90 days preceding index date
Non-potassium sparing diuretics
Potassium sparing diuretics
Beta-adrenergic receptor antagonists
Potassium supplements
Non-steroidal anti-inflammatory drugs
Angiotensin converting enzyme inhibitors
Angiotensin receptor blockers
Direct renin inhibitors
Calcium channel blockers
Digoxin
Antiarrhythmic drugs
Nitrates
Anticoagulants
Aspirin and other antiplatelet drugs
Statins
Fibrates
Oral hypoglycemic
Insulin
Antipsychotics
Antidepressants
Prokinetics
Opiates
Sedative hypnotics
Cholinesterase inhibitors

Comorbidities in past 5 years:
Congestive heart failure
Chronic kidney disease
Myocardial infarction
Angina
Stroke/transient ischemic attach
Diabetes
Hypertension
Pneumonia
Cardiomyopathy

Procedures in past 5 years:
Angiography
Coronary artery bypass graft
Carotid Doppler ultrasonography
Carotid endartectomy

Echocardiography
Electrocardiogram
Holter monitor
Nuclear medicine stress test
Percutaneous transluminal coronary angioplasty
Permanent pacemaker insertion
Valve surgery

Emergency department visit in past year
Cardiologist visit in past year
Number of prescription drugs in past year
Socioeconomic status (income quintiles)
Charlson co-morbidity index
Living in long-term care facility

Supplementary analysis with congestive heart failure as a covariate

Table 4. Antibiotic use and the risk of sudden death within 7 days

Antibiotic use	Cases No. (%)	Controls No. (%)	Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)*
Amoxicillin (reference)	226 (22.0)	1098 (29.4)	1.0 (reference)	1.0 (reference)
Co-trimoxazole	288 (28.0)	734 (19.7)	1.83 (1.50 to 2. 24)	1.40 (1.10 to 1.77)
Ciprofloxacin	340 (33.1)	964 (25.8)	1.66 (1.37 to 2.00)	1.31 (1.04 to 1.64)
Norfloxacin	79 (7.7)	455 (12.2)	0.81 (0.61 to 1.08)	0.73 (0.52 to 1.02)
Nitrofurantoin	94 (9.2)	482 (12.9)	0.87 (0.66 to 1.15)	0.63 (0.45 to 0.87)

*Analysis adjusted for congestive heart failure and the disease risk index

Table 5. Antibiotic use and the risk of sudden death within 14 days

Antibiotic use	Cases No. (%)	Controls No. (%)	Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)*
Amoxicillin (reference)	418 (22.9)	2021 (29.8)	1.0 (reference)	1.0 (reference)
Co-trimoxazole	474 (25.9)	1262 (18.6)	1.80 (1.54 to 2.09)	1.53 (1.28 to 1.82)
Ciprofloxacin	603 (33.0)	1888 (27.9)	1.50 (1.30 to 1.72)	1.17 (0.99 to 1.39)
Norfloxacin	158 (8.6)	832 (12.3)	0.89 (0.73 to 1.09)	0.83 (0.65 to 1.04)
Nitrofurantoin	174 (9.5)	768 (11.3)	1.08 (0.88 to 1.32)	1.02 (0.81 to 1.30)

*Analysis adjusted for congestive heart failure and the disease risk index

Supplementary analysis to approximate the absolute risk of sudden death

Table 6: Sudden death within 14 days of co-trimoxazole or amoxicillin prescriptions

Co-trimoxazole	
Number of sudden deaths within 14 days	674
Total number of prescriptions	215,941
Sudden death per 1000 prescriptions	3.1
Amoxicillin	
Number of sudden deaths within 14 days	583
Total number of prescriptions	446,300
Sudden death per 1000 prescriptions	1.3

Note: in this analysis a patient taking an ACE or ARB may have multiple prescriptions for cotrimoxazole

Because case-control studies cannot provide estimates of absolute risk, we conducted a supplementary analysis to contextualize our results. We determined the number of sudden cardiac deaths within 2 weeks of a prescription for co-trimoxazole among patients taking either an ACEI or ARB (numerator), relative to the total number of prescriptions for co-trimoxazole in the same subset of patients (denominator). This exercise was repeated for amoxicillin.